Targeting the EGFR and FGFR cellular pathways for bile duct cancer

by Steve Yozwiak

Researchers at the Translational Genomics Research Institute (TGen) and physicians at Mayo Clinic's Individualized Medicine Clinic have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies.

Potential new treatment approaches are being validated to develop new tests that physicians can use to guide therapy for this aggressive of the bile ducts that progresses quickly and is difficult to treat.

Clinically important findings suggest that targeting the EGFR and FGFR cellular pathways may benefit thousands of patients with this disease, according to the study published today in the journal PLOS Genetics.

Half of the patients treated in this study responded to either ponatinib (typically used for certain types of leukemia) or pazopinib (a kidney cancer drug), depending on the identified through sequencing.

"In 3 out of the 6 patients we analyzed, we found compelling, treatable and unexpected genetic alterations that would never have been found by normal testing methods for cholangiocarcinoma," said Dr. Mitesh Borad, a Mayo Clinic oncologist and lead author of the paper. "We treated these three patients with drugs that attack these genetic alterations and saw tumor shrinkage. This gives us hope for better treatments for this aggressive, hard-to-treat cancer."

Because of these encouraging early results, the team of 49 doctors and researchers proposes large-scale clinical trials to test EFGR and FGFR inhibitors as possible treatments for biliary tract cancers that harbor mutations in these genes and pathways.

"Our results demonstrate that if we find the right molecular context, more appropriate therapies can be chosen that improve outcomes," said Dr. John Carpten, TGen Deputy Director of Basic Science and Director of TGen's Integrated Cancer Genomics Division, and the study's senior author. "We now hope to design larger clinical studies to treat patients' tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced ."

Bile duct cancer is a rare cancer that occurs mostly in people older than age 50. Surgical approaches, such as resection and liver transplantation, represent the only curative treatment approaches, said Dr. Borad. Most , however, present with surgically unresectable or metastatic disease at the time of diagnosis. Standard-of-care chemotherapies are not curative and there is an unmet need for newer approaches, Dr. Borad added.

add to favorites email to friend print save as pdf

Related Stories

Whole genome sequencing of rare olfactory neuroblastoma

May 23, 2012

The Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma ...

Recommended for you

Science of romantic relationships includes gene factor

10 hours ago

(Medical Xpress)—Adolescents worry about passing tests, winning games, lost phones, fractured bones—and whether or not they will ever really fall in love. Three Chinese researchers have focused on that ...

Stress reaction may be in your dad's DNA, study finds

Nov 21, 2014

Stress in this generation could mean resilience in the next, a new study suggests. Male mice subjected to unpredictable stressors produced offspring that showed more flexible coping strategies when under ...

More genetic clues found in a severe food allergy

Nov 21, 2014

Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the ...

Brain-dwelling worm in UK man's head sequenced

Nov 20, 2014

For the first time, the genome of a rarely seen tapeworm has been sequenced. The genetic information of this invasive parasite, which lived for four years in a UK resident's brain, offers new opportunities ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.